Citations

Clear

912 citation(s) found for "Yu, Caroline".

Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review
Lommer, Caroline , Schroeder, Lila, Amato, Caroline, Dhakal, Kerry , Kotian, Caitlin, Quiroga, Dionisia , Paskett, E., Fu, Mei , Collins, Stephanie, King, T. A., McLaughlin, Sarah A. , Myers, Sara P. , Paskett, Electra D. , McAlearney, Ann Scheck

Mayo Clinic

Frontiers in Oncology | March 4, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fonc.2026.1751628 | PMID 41858365 Get It

Background Breast cancer-related lymphedema (BCRL) is a common and life-long adverse event affecting ~20% of breast cancer survivors. As existing non-pharmacologic management is burdensome, expensive, and variably effective, this systematic scoping review aims to identify pharmacologic and herbal agents for prevention and treatment for BCRL. Methods PubMED, Embase, Web of Science Core collection, and the Cumulative Index to Nursing and Allied Health Literature were searched for studies published in English between 1993 and 2025 that investigated the preventative or therapeutic effect of pharmacologic or herbal agents on BCRL among adult stage I-III breast cancer patients. Studies describing interventions with systemically absorbed anti-inflammatories, anti-thrombotics, anti-coagulants, and blood product components were included. Systematic reviews, protocols for ongoing clinical trials, preclinical and non-human studies, editorials, and studies not exclusive to BCRL were excluded. Three reviewers screened and extracted data between June and August 2025. The primary outcomes of interest were reduction in BCRL incidence or severity. Results Of the 217 articles screened, 37 were included in the final review. After full text review, 13 were excluded for repetitive data, non-English language, or irrelevant outcomes. The 24 studies included in the analysis investigated anti-diabetic, herbal, anti-inflammatory, anti-hypertensive, immunomodulatory, and microbiome modifying agents, and venoactive flavinoid derivates. Three studies explored the role of pharmacologic/herbal agents in BCRL prevention. While thiazolidinediones, anti-hypertensives, and non-steroidal anti-inflammatory drugs (NSAIDs) had no effect on BCRL incidence, glucagon-like peptide-1 receptor agonists (GLP-1 RA) were associated with BCRL prevention. In the 21 studies that assessed the effect of pharmacologic/herbal agents in BCRL treatment, NSAIDs/steroids, anti-hypertensives, microbiome/synbiotic supplements, and doxycycline showed no benefit and data for flavonoid-derived venoactive agents and herbal products were inconsistent. Immune-modulating therapies were associated with improved BCRL signs/symptoms in three studies. Conclusion This systematic scoping review found limited evidence suggesting that GLP-1 RAs may reduce the risk of BCRL and that immunomodulatory agents may improve signs/symptoms of BCRL. Rigorous prospective trials using standardized limb volume/edema, quality-of-life (QoL), and symptom measures and longer follow-up are needed to inform clinical practice aimed at preventing and treating BCRL. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251055134.
Nationwide Mammographic Screening Among a Large Population of Underserved Subgroups
Cathcart-Rake, Elizabeth , Thao, Viengneesee , Le‐Rademacher, Jennifer , Helfinstine, David A. , Ruddy, Kathryn, Vachon, CM, Davidge-Pitts, Caroline, Carroll, Evelyn F. , Scout, N F N, Ridgeway, Jennifer L. , Shufelt, Chrisandra , Jatoi, Aminah , Scout, NFN , Cathcart-Rake, Elizabeth J , Ruddy, Kathryn J , Vachon, Celine M. , Carroll, Evelyn, Scout, Nfn , Shufelt, Chrisandra L , Tevaarwerk, Amye J , Jatoi, Aminah , Le-Rademacher, Jennifer G , Ridgeway, Jennifer L , Ruddy, Kathryn J. , Davidge‐Pitts, Caroline , Tevaarwerk, Amyé

Mayo Clinic

Journal of Clinical Oncology | March 3, 2026 | Volume: 44 | Issue: 11 | Pages: 981-991

10.1200/jco-25-01659 | PMID 41774876 Get It

PURPOSE This national study was undertaken to determine screening mammography rates among transgender and gender diverse (TGD) individuals. METHODS TGD individuals and cisgender women who qualified to receive screening mammography based on American College of Radiology guidelines were identified in the longitudinal OptumLabs Data Warehouse. The primary end point was the percentage of patients who had high rates of screening (>75% recommended screenings). Multivariable analyses were conducted in a matched population of transgender men to cisgender women to identify and adjust for factors associated with high adherence. Individuals were matched at a 1:4 ratio (transgender men: cisgender women) on age, race/ethnicity, year of enrollment in their health care plan, and duration of follow-up. RESULTS This study focused on 10,478 TGD individuals (3,778 transgender men; 1,294 transgender women; 5,406 with gender dysphoria not meeting other TGD criteria, NMOT) and 6,218,369 cisgender women. For transgender men, transgender women, individuals with gender dysphoria NMOT, and cisgender women, high mammography rates were observed in 41.1% (95% CI, 39.5 to 42.6), 7.4% (95% CI, 6.0 to 8.8), 11.9% (95% CI, 11.0 to 12.7), and 38.3% (95% CI, 38.3 to 38.4), respectively ( P < .0001). When transgender men were compared with 15,112 matched cisgender women, an age-based differential association was observed between sex and high mammography rates (interaction P = .0003); compared with cisgender women, transgender men appeared more likely to manifest high rates of screening at age 40-49 years (odds ratios [ORs], 1.38 [95% CI, 1.28 to 1.50]; P < .0001) and 50-59 years (OR, 1.57 [95% CI, 1.35 to 1.81]; P < .0001) but not in the older age groups. CONCLUSION The relatively high rates of screening mammography in cisgender women and transgender men suggest clinicians are offering mammography to individuals who are at average or high breast cancer risk, as compared with cisgender women, and not to transgender women at low risk.
In Vivo Selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft model
Wilbanks, Brandon , Wilbanks, Brandon A , III, Louis James Maher , Doherty, Caroline , Jain, Sonia , Ott, Lauren L. , Bakken, Katie, Burgenske, Danielle M. , Pearson, Keenan , Griffith, Jessica I. , Tian, Zichen, Meridew, Jeffrey A., Yerneni, Saigopalakrishna S. , Elmquist, William F. , Sarkaria, Jann N.

Mayo Clinic

No container title available | February 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.16.706148 | PMID 41756849 Get It

Abstract Glioblastoma (GBM) is an aggressive, high-grade glioma with a near-universally fatal prognosis. Therapeutic failure is often attributed to the highly selective blood brain barrier (BBB), the diffuse infiltrative nature of the tumor, and the marked intratumoral heterogeneity of GBM. Although antibody drug conjugates ADCs have shown promise for high grade gliomas such as GBM, efficacy is limited by ADC size. Aptamers—short, synthetic, single-stranded DNA or RNA molecules—can be ∼6-fold lower in molecular weight than IgG antibodies and have the potential to cross the intact BBB. Unlike other nucleic acid-based therapies, aptamer function arises from three-dimensional shape rather than genetic coding. Here we aim to replace the targeting component of the ADC paradigm with a DNA aptamer, thus creating an aptamer-drug conjugate (ApDC). We employed in vivo SELEX using an orthotopic patient-derived xenograft (PDX) GBM mouse model and a vast (∼100 trillion 80-mer sequences) ApDC library. We report the results from this first in vivo ApDC selection of its kind. We characterize target tissue binding ex vivo , cell association, biodistribution, and pharmacokinetics from this selection. This study exemplifies an unbiased approach to a problem that rational design has yet to overcome, offering a new direction for GBM therapeutic development.
Obesity in Living Kidney Donors from Risk to Ethics
Budhiraja, Pooja , Denic, Aleksandar, Issa, Naim , McKee, Katie, Schinstock, Carrie, Taler, Sandra J. , Heimbach, Julie K. , Mirie, Kayla R., Ty, Diwan S, Kukla, Aleksandra, Đenić, Aleksandar , Bzoma, Beata , Denic, Aleksandar , Issa, Naim , Taler, Sandra J , Heimbach, Julie K , Jadlowiec, Caroline , Mirie, Kayla R , Diwan, Tayyab , Kukla, Aleksandra , Budhiraja, Pooja , Bzoma, Beata , Chakkera, Harini A. , Jadlowiec, Caroline C. , Kukla, Aleksandra

Mayo Clinic

Clinical Journal of the American Society of Nephrology | February 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2215/cjn.0000001030 | PMID 41701547 Get It

Obesity is increasingly prevalent among living kidney donor candidates, presenting complex clinical, ethical, and logistical challenges. Although obesity is linked to increased post-donation hypertension, diabetes, proteinuria, and chronic kidney disease, the overall absolute risks are modest and may differ depending on metabolic health and patterns of fat distribution. Current reliance on body mass index alone fails to capture the full spectrum of obesity-related risks, leading to inconsistent donor selection practices and potential inequities. This review examines the pathophysiological mechanisms of obesity-related kidney injury and available evidence on comorbidities and postdonation outcomes related to obesity. We discuss tools for better risk stratification, such as imaging-based adiposity assessment and personalized weight management strategies, and note that some risks may remain after weight loss. Barriers such as rigid body mass index cutoffs, limited access to treatment, and lack of long-term follow-up exacerbate disparities in access to donation. We argue for a shift toward individualized, risk-based evaluation supported by multidisciplinary care. We underscore the importance of donor counseling and advocate for a comprehensive, rather than paternalistic approach to living kidney donor selection. Advancing safe and equitable living donation in the context of rising obesity rates will necessitate revised guidelines, improved access to treatment, and an ongoing commitment to donor well-being.
International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG
Marchegiani, Giovanni, Hegyi, Peter, Archibugi, Livia, Valente, Roberto, Capurso, Gabriele, Witt, Heiko, Bonovas, Stefanos , Maisonneuve, Patrick, Verbeke, Caroline S., Dominguez‐Muñoz, J. Enrique, Scheers, Isabelle, Czakó, László, Wagner, R, Rebours, Vinciane, Öhlund, Daniel, Gubergrits, N. B. , Engjom, Trond , Neeße, Albrecht , Apte, Minoti V. , Braren, Rickmer, Bunduc, Stefania, Ceyhan, Güralp Onur, Chouhan, Manil Dinesh, Couvelard, Anne, Iglesia, Daniel de la, Drewes, Asbjørn Mohr, Sarasqueta, A. Farina, Francque, Sven, Frøkjær, Jens Brøndum, Iglesias‐Garcia, Julio, Garg, Pramod, Gerst, Felicia, Gulbinas, Antanas, Gürcinar, Ibrahim Halil, Heni, Martin , Jonas, E G, Kitano, M., Krag, Aleksander, Laukkarinen, J., Lipp, Mónika, Loveček, M., Martignoni, Marc E., Masip, Etna , Matsumoto, Ryotaro , Mozhynа, T. L. , Nosáková, Lenka, Ockenga, Johann , Pandanaboyana, Sanjay, Panić, Nikola , Papachristou, Georgios, Pasqua, Analía V. , Pawlak, Katarzyna Monika, Regel, Ivonne , Regnér, Sara, Singh, Vijay Kumar , Smits, M., Sung, Min Je , Tacelli, Matteo, Teutsch, Brigitta, Udrescu, Mihaela, Wilschanski, Michael , Yavas, Aslihan, Zamboni, G., Löhr, J. Matthias, Singh, Vijay , Drewes, Asbjørn Mohr , Regnér, Sara , Krag, Aleksander , Marchegiani, Giovanni , Pawlak, Katarzyna M. , Marchegiani, Giovanni , Hegyi, Peter , Archibugi, Livia , Bonovas, Stefanos , Verbeke, Caroline S , de-Madaria, Enrique , Wagner, Robert , Rebours, Vinciane , Öhlund, Daniel , Neesse, Albrecht , Bezmarević, Mihailo , Bunduc, Stefania , Iglesia, Daniel de la , Drenth, Joost P H , Gürcinar, Ibrahim Halil , Jonas, Eduard , Kitano, Masayuki , Obmann, Verena , Pandanaboyana, Sanjay , Pasqua, Analia Verónica , Pawlak, Katarzyna M , Regnér, Sara , Seicean, Andrada , Sung, Min Je , Taylor, Roy , Singh, Vijay P , Krag, Aleksander , Vujasinović, Miroslav , Demir, İhsan Ekin , Hegyi, Péter , Valente, Roberto, Capurso, Gabriele , Piovani, Daniele , Rosendahl, Jonas , Maisonneuve, Patrick , Karçaaltıncaba, Muşturay , Domínguez‐Muñoz, J. Enrique , Scheers, Isabelle , Czakó, László , Idılman, Ilkay S. , Overbeek, Kasper A. , Braren, Rickmer , Chouhan, Manil Dinesh , Couvelard, Anne , Cros, Jerome F. , de‐Madaria, Enrique , Drenth, Joost P.H. , Fracasso, Pierluigi , Francque, Sven , Frøkjær, Jens Brøndum , Iglesias‐García, Julio , Garg, Pramod, Gulbinas, Antanas , Hyun, Jong Jin , Jonas, Eduard , Kiriukova, Mariia A. , Laukkarinen, Johanna , Loveček, Martin , Molven, Anders , Nosáková, Lenka , Obmann, Verena Carola , Papachristou, Georgios I. , Peláez‐Luna, Mario , Robinson, Stuart Michael , Smits, Mark M. , Tacelli, Matteo , Teutsch, Brigitta , Udrescu, Mihaela, Yavas, Aslihan , Zamboni, Giulia Angela, Löhr, J.-Matthias

Mayo Clinic

United European Gastroenterology Journal | February 14, 2026 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/ueg2.70185 | PMID 41689768 Get It

ABSTRACT This international, multidisciplinary consensus report represents the first effort to systematically define and characterize fatty pancreas. A key outcome of this endeavor was the recommendation to adopt “fatty pancreas” as the standardized and inclusive term to describe all forms of fat accumulation in the pancreas. This terminological consensus provides a critical foundation for unified reporting and clinical communication. Another major contribution of the report is the consensus on diagnostic imaging findings, which was based on radiological and endoscopic modalities. The proposed criteria aim to enhance consistency in clinical assessment and support the development of standardized research protocols. In addition to establishing terminology and diagnostic frameworks, the report also synthesizes current knowledge across a wide range of relevant domains. These include the etiology and epidemiology of fatty pancreas, as well as its associations with alcohol consumption, smoking, acute and chronic pancreatitis, pancreatic exocrine insufficiency, type 2 diabetes mellitus, and surgical outcomes. The potential links between fatty pancreas and neoplastic conditions such as intraductal papillary mucinous neoplasms and pancreatic cancer are also addressed, alongside the current understanding of its metabolic implications (beta‐cell function and glucose homeostasis) and treatment strategies. Throughout the consensus process, a consistent theme emerged: the limited availability of high‐quality, prospective clinical data. Therefore, many of the recommendations in this report are based on expert consensus rather than strong empirical evidence. As such, the statements require rigorous prospective validation before they can be adopted into routine clinical practice. This underscores a critical need for further research, particularly studies aimed at clarifying causal relationships, validating diagnostic tools, and determining the clinical relevance of fatty pancreas across diverse patient populations. This report serves as both a summary of our current understanding and a roadmap for future investigations, aiming to close existing knowledge gaps and guide evidence‐based clinical practice in this emerging field.
Dacryocystorhinostomy Practice Patterns Among ASOPRS Members: A Shift in Preferences and Attitudes
Figueroa, Giorgio Sanchez, Figueroa, Nicole Sanchez, Abdelsalam, Alaa , Yu, Caroline , Bradley, E., Tooley, Andrea A. , Griepentrog, Gregory J. , Wagner, Lilly H. , Figueroa, Nicole Gabriela Sanchez , Sanchez Figueroa, Nicole, Yu, Caroline Y, Sanchez Figueroa, Nicole Gabriela , Figueroa, Giorgio Rafael Sánchez

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | February 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/iop.0000000000003188 | PMID 41687079 Get It

Purpose: To determine current dacryocystorhinostomy (DCR) practice patterns of American Society of Ophthalmic Plastic and Reconstructive Surgery members and identify surgeon and case-related factors impacting preference for endoscopic versus external DCR and the use of preoperative imaging. Methods: A cross-sectional web-based anonymous 16-question survey was distributed to 277 American Society of Ophthalmic Plastic and Reconstructive Surgery members enrolled in survey-based research. The survey assessed surgeons’ demographics, practice settings, surgical preferences, and imaging practices. Responses were summarized and compared using statistical tests for frequency distribution. Results: A total of 111 surgeons (40.0%) responded to the survey. Utilization of endoscopic DCR (endoDCR) was highly variable, with 57% of junior surgeons (<5 years in practice) using it for >66% of their cases, compared with only 18.3% of surgeons with >15 years postfellowship experience. High utilization of endoDCR (>66% of cases) was more common in academic surgeons compared with private practice (48.4% vs. 19.6%, p < 0.01). The most cited reasons for endoDCR were scar avoidance and revision surgery. For external DCR, anatomical barriers and concern for mass/need for biopsy were common indications. Most surgeons only order imaging for certain indications, such as prior sinonasal surgery, facial trauma, suspected tumor, or atypical presentation. Conclusion: Utilization of endoDCR was correlated with years in practice, with younger surgeons preferring the endoscopic technique. A large majority felt that the relevance of imaging is low in most patients. Future research is needed to standardize case-based indications for endoscopic versus external approaches and preoperative imaging.
Factors Affecting Outcomes of Hindfoot Fusion Nails for Acute Injury: A Multicenter Study
Kim, Eugene , Tornetta, Paul , Carlson, Jon, Schultz, Alex, Wireman, Garrett , Ollivere, Benjamin J., Zheng, Amy , Patch, David , White, Tim D. , Heinz, Nicholas , Lahurd, Caroline Elizabeth, Ostrum, Robert F. , Baumann, Charles, Kottmeier, Stephen, Doany, Michael E. , Krause, Peter, Redlich, Nathan, Egol, Kenneth, Konda, Sanjit, Mir, Hassan, McCaskey, Meghan , Azer, Emil, Kusler, Jace E. , Beltran, Michael T., Mehta, Samir, Masada, Kendall M. , Hidden, Krystin A., Kuttner, Nicolas P. , Tornetta, Paul , Beltran, Michael J. , Kuttner, Nicolas, Schultz, Alexander , Ollivere, Ben J. , Zheng, Amy, Spitler, Clay A. , White, Tim, Stinner, Daniel J. , Baumann, Charles A. , Krause, Peter C. , Egol, Kenneth A. , Konda, Sanjit R. , Beltran, Michael, Mehta, Samir D. , Hidden, Krystin A.

Mayo Clinic

Journal of Orthopaedic Trauma | February 13, 2026 | Volume: 40 | Issue: 3 | Pages: 148-154

10.1097/bot.0000000000003104 | PMID 41685944 Get It

OBJECTIVE: To evaluate the effect of joint preparation and patient factors on outcomes and complications in patients treated acutely with hindfoot fusion nails for ankle and pilon fractures. METHODS: Design: Retrospective chart review. Setting: Thirteen US trauma centers and 2 UK trauma centers. Patient Selection Criteria: Ankle and pilon fractures (AO-OTA types A-C) from 2010 to 2020 acutely treated definitively with hindfoot fusion nail were reviewed. Patients at least 18 years old and with minimum 6 months follow-up or earlier diagnosis of complication were included. Exclusion criteria included nonambulatory at baseline, prior internal fixation that failed and underwent revision, and prior tibiotalar or subtalar arthrodesis. Outcome Measurements and Comparisons: The primary outcome was final postoperative ambulatory status. Secondary outcomes were infectious and fracture-related complications. RESULTS: One hundred forty-nine patients (75 men; 74 women; age 20–99; median 63 years) were treated for ankle (104) or pilon (45; 8A, 13B, 24C) fractures. Eighty-five patients (44%) had open fractures and 55 (37%) had diabetes. Thirty-six patients (24%) had joint preparation at the time of surgery. Forty-five (30%) were made weight bearing as tolerated postoperatively; the median time to mobilize was 1.5 days (0–210) and to full weight bearing was 35 days (0–1462). Fifty-seven patients (85%) returned to their preinjury ambulatory status, which was not affected by joint preparation (50% vs. 59%, P = 0.327). Joint preparation led to higher articular fusion rates (94% vs. 24%; P = 0.001) and fewer hardware removals (19% vs. 42%, P = 0.013), but trended toward a higher fracture nonunion rate (19% vs. 8%, P = 0.053). Forty-five patients (30%) had infectious complications, 60 (40%) had a fracture-related complication, and 67 (45%) had additional procedures. Open fractures did not lead to any differences in superficial or deep infection. Insulin-dependent diabetes was associated with higher rates of infectious complications (31% vs. 15%, P = 0.028) and amputation (17% vs. 4%, P = 0.029). CONCLUSIONS: Hindfoot fusion nails for acute ankle and pilon injuries had high complication rates. More complications occurred in patients with insulin-dependent diabetes. While 95% regained ambulation, only 57% returned to preoperative status. Joint preparation led to higher rates of articular fusion (94% vs. 24%, P < 0.001) but not fracture union (81% vs. 66%, P = 0.106). LEVEL OF EVIDENCE: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer
Light, Alexander, Peters, Max, Arya, Manit, Tanaka, Mariana Bertoncelli , Dudderidge, Tim , Emberton, Mark, Grey, Alistair , Hindley, Richard, Laniado, Marc, McCraken, Stuart, Moore, Caroline M., Nigam, Raj , Noureldin, Mohamed , Reddy, Deepika, Virdi, Jaspal, Ahmed, Mohamed, Albisinni, Simone, Cathcart, P. , Joniau, S., Karnes, Robert Jeffrey, Persad, Raj , Rajwa, Paweł, Sanchez-Salas, Rafael, Shariat, Shahrokh F., Smith, Joseph A., Tilki, Derya, Poel, H. G. van der, Calleris, Giorgio , Gontero, P., Marra, Giancarlo, Ahmed, Hashim U., Joniau, Steven , Emberton, Mark , Rajwa, Paweł , Moore, Caroline M. , Joniau, Steven , Rajwa, Pawel , Light, Alexander J. W., Peters, Max , Emara, Amr M. , Moore, Caroline , Orczyk, Clément , Reddy, Deepika , Albisinni, Simone , Karnes, R. Jeffrey , Shariat, Shahrokh F. , Tilki, Derya , Poel, HG van der, Marra, Giancarlo , Ahmed, Hashim U. , Shah, Taimur Tariq

Mayo Clinic

JAMA Oncology | February 12, 2026 | Volume: 12 | Issue: 4 | Pages: 364

10.1001/jamaoncol.2025.6448 | PMID 41678176 Get It

Importance Patients with recurrent prostate cancer after previous radiotherapy typically have poor survival. Those with recurrences prostate confined might be suitable for salvage focal therapy (sFT) or salvage radical prostatectomy (sRP). sFT may offer good cancer control with comparatively less toxic effects, but outcomes beyond 5 years have not been reported, and no study has compared sFT to sRP. Objective To compare cancer control and perioperative complications among patients after sFT vs sRP. Design, Setting, and Participants In this international, multicenter cohort study of matched comparison data, patients undergoing sFT were derived from the prospective UK HIFU (high-intensity focused ultrasound) Evaluation and Treatment and International Cryotherapy Evaluation registries (9 centers; 2006-2024) and the prospective UK Focal Recurrent Assessment and Salvage Treatment cohort study (6 centers; 2014-2018). Patients undergoing sRP were derived from an international retrospective registry (12 centers in 8 countries; 2000-2021). Patients with biopsy-confirmed, localized recurrent prostate cancer postradiotherapy, either external beam radiotherapy, brachytherapy, or both, were included. Data were analyzed from March to July 2025. Exposures sFT using HIFU or cryotherapy vs sRP. Main Outcomes and Measures The primary outcome was cancer-specific survival up to 10 years. Secondary outcomes were overall survival, any perioperative complications (Clavien-Dindo grades 1-5), and major perioperative complications (Clavien-Dindo grades 3-5). Comparisons were made on matched patients following 1:1 cardinality matching within individual multiply-imputed datasets. Matching variables used were radiotherapeutic treatment, years between primary and salvage treatments, European Association of Urology recurrence risk group, and presalvage age, prostate-specific antigen, prostate volume, grade group, T stage, and androgen-deprivation therapy use. Results A total of 923 patients were eligible for matching (419 undergoing sFT and 504 undergoing sRP). Of the patients undergoing sFT, 325 (77.6%) underwent HIFU and the remainder cryotherapy, with 241 (57.5%) treated with quadrant ablation. Of patients treated with sRP, 376 (74.6%) underwent open surgery and the remainder robot-assisted surgery. For sFT vs sRP, 10-year cancer-specific survival was 92% (95% CI, 86%-98%) vs 99% (95% CI, 97%-100%), with no statistically significant difference (restricted mean time lost, −0.09 years; 95% CI, −0.22 to 0.03 years; P = .15; subdistribution hazard ratio, 0.45; 95% CI, 0.05-4.00; P = .47). There was no statistically significant difference in 10-year overall survival (restricted mean survival time, −0.13 years; 95% CI, −0.86 to 0.60 years; P = .72). Undergoing sRP was associated with statistically significant higher odds of any complication (adjusted odds ratio, 24.20; 95% CI, 12.94-45.27; P &amp;lt; .001) and major complication (adjusted odds ratio, 9.31; 95% CI, 3.42-25.36; P &amp;lt; .001). Conclusions and Relevance In this cohort study, sFT and sRP were effective for treating localized radiorecurrent prostate cancer, while sFT was associated with fewer perioperative complications. sFT may provide a favorable therapeutic ratio for many patients with localized radiorecurrent prostate cancer.
Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling
Dutt, Shubir , Leichter, Dana, Wolf, Amy , Kornak, John , Clark, Annie L , Russell, Lucy L. , Bouzigues, Arabella , Cash, David M, Bocchetta, Martina , Olzinski, Molly, Ece, Bayram, Borroni, Barbara, Butler, Chris R., Clark, David, Convery, Rhian S., Darby, R. Ryan , Mendonça, Alexandre de, Dickerson, Bradford, Domoto‐Reilly, Kimiko, Ducharme, Simon, Ferry‐Bolder, Eve, Finger, Elizabeth, Foster, Phoebe H. , Galasko, Douglas R., Galimberti, Daniela, Gerhard, Alexander, Ghoshal, Nupur , Graff, Caroline, Graff‐Radford, Neill, Grant, Ian M., Hales, Chadwick M., Honig, Lawrence S., Hsiung, Ging‐Yuek, Huey, Edward D, Irwin, David John, Jiskoot, Lize C., Kremers, Walter K. , Kwan, Justin Y., Laforce, Robert, Ber, Isabelle Le, Levin, J, Litvan, Irene, Mackenzie, Ian R., Masellis, Mario, Mendez, Mario F., Moreno, Fermin, Onyike, Chiadi U. , Otto, M, Pascual, Belen, Pressman, Peter , Rademakers, Rosa, Ramos, Eliana Marisa , Ritter, Aaron, Roberson, Erik D. , Sánchez‐Valle, Raquel, Santana, Isabel, Seelaar, Harro, Snyder, Allison, Sorbi, Sandro, Synofzik, Matthis, Tartaglia, Maria Carmela, Swieten, John C. van, Vandebergh, Marijne , Vandenberghe, Rik, Heuer, Hilary W. , Miller, Bruce L., Seeley, William W., Gorno‐Tempini, Maria Luisa, Kramer, Joel H., Forsberg, Leah K., Kantarci, Kejal, Boeve, Bradley F., Boxer, Adam L. , Rohrer, J. D., Rosen, Howard J., Staffaroni, Adam M., investigators, FTD Prevention Initiative (FPI), Graff, Caroline , Galimberti, Daniela , Otto, Markus , Jiskoot, Lize C. , Moreno, Fermín , Domoto‐Reilly, Kimiko , Russell, Lucy L , Bocchetta, Martina , Bayram, Ece , Ducharme, Simon , Finger, Elizabeth C. , Galimberti, Daniela , Ghoshal, Nupur , Irwin, David J , Kwan, Justin Y , Le Ber, Isabelle , Otto, Markus , Pascual, Belen , Snyder, Allison , Synofzik, Matthis , Tartaglia, Maria Carmela , Tiraboschi, Pietro , Kantarci, Kejal , Rohrer, Jonathan D , Roberson, Erik , Kremers, Walter K , Domoto-Reilly, Kimiko , Vandebergh, Marijne , Bouzigues, Arabella , Jiskoot, Lize C , Graff, Caroline , Cobigo, Yann , Cash, David M. , Appleby, Brian S. , Borroni, Barbara , Bozoki, Andrea C , Clark, David, Convery, Rhian , Mendonça, Alexandre de , Ducharme, Simon , Ferry‐Bolder, Eve , Galasko, Douglas , Gerhard, Alexander , Graff‐Radford, Neill R. , Hales, Chadwick M. , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kwan, Justin , Laforce, Robert , Ber, Isabelle Le , Léger, Gabriel C. , Xiong, Chengjie , Litvan, Irene , Mackenzie, Ian R. , Masellis, Mario , Mendez, Mario F. , Pascual, Belén , Rademakers, Rosa , Rowe, James B. , Sánchez‐Valle, Raquel , Santana, Isabel , Seelaar, Harro , Snyder, Allison , Sorbi, Sandro , Synofzik, Matthis , Tiraboschi, Pietro , Swieten, John C. van , Vandenberghe, Rik , Seeley, William W. , Gorno‐Tempini, Maria‐Luisa, Kramer, Joel H. , Forsberg, Leah K. , Kantarci, Kejal , Boeve, Bradley F. , Rohrer, Jonathan D. , Rosen, Howard J. , Staffaroni, Adam M.

Mayo Clinic

Annals of Neurology | January 29, 2026 | Volume: 99 | Issue: 5 | Pages: 1315-1326

10.1002/ana.78167 | PMID 41608854 Get It

Objective Age of symptom onset is highly variable in familial frontotemporal lobar degeneration (f‐FTLD). Accurate prediction of onset would inform clinical management and trial enrollment. Prior studies indicate that individualized maps of brain atrophy can predict conversion to dementia in f‐FTLD. We used a Bayesian linear mixed‐effect (BLME) prediction method for identifying accelerated brain volume loss to predict conversion to dementia. Methods Participants included 234 asymptomatic or prodromal carriers of C9orf72 , GRN , or MAPT mutations (including 21 dementia converters) with ≥3 longitudinal magnetic resonance imaging (MRI) T1‐weighted scans. The BLME models established individual voxel‐wise gray matter trajectories using the first 2 scans. Person‐specific clusters of accelerated volume loss were estimated in subsequent scans and tested as predictors of dementia conversion compared with other approaches in time‐varying Cox proportional hazard models covarying for age. Receiver‐operating characteristic (ROC) curves estimated utility of cluster volume in discriminating which participants converted to dementia within 24 months. Results The BLME cluster volume predicted conversion to dementia in f‐FTLD mutation carriers overall and separately in C9orf72 , GRN , and MAPT , with comparable hazard ratios observed for atrophy W‐maps and regional volumes. Within a 24‐month timeframe, BLME cluster volume discriminated dementia converters from non‐converters with larger areas under the curve (AUCs) than other approaches. Interpretation Bayesian‐modeled individualized atrophy scores predict dementia progression among asymptomatic f‐FTLD mutation carriers and may have increased utility compared with other structural imaging methods when studying individuals over shorter timeframes that align with clinical trial design. ANN NEUROL 20269999:n/a–n/a
Medicare Anesthesiology Teaching Funding Restoration Act of 2007: Its Legislative Course, and Financial, Educational, and Advocacy Impacts
Johnstone, Robert E., Ensor, Caroline L., Mueller, Jeffrey T., Gal, Jonathan S. , Johnstone, R E , Mueller, Jeffrey T.

Mayo Clinic

Anesthesiology Open | January 27, 2026 | Volume: 1 | Issue: 1 | Pages: e0003

10.1097/ao9.0000000000000003 Get It

In 1995, Medicare reduced payments by 50% for anesthesiologists teaching two residents concurrently. By 2004, anesthesiology residency programs were losing, on average, $400,000 per year, causing many institutions to close their anesthesiology training programs. American Society of Anesthesiologists leaders tried unsuccessfully for several years to address this situation through appeals to Medicare. They then organized an advocacy effort to pass the Medicare Anesthesiology Teaching Funding Restoration Act of 2007, which in 2010 restored full payments for teaching anesthetics. From 2010 through 2024, anesthesiologists received $1.262 billion from Medicare for 2.8 million cases involving residents, which is between $442 million and $568 million more than if the legislation had not been enacted. Anesthesiology residency programs increased from 131 to 167 after the enactment. This historic legislation taught anesthesiologists that changing Medicare policies may require congressional action and that persistent and broad-based advocacy can make a legislative campaign successful.